İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2021 · article

The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

YÖKSİS OpenAlex Açık erişim · diamond TR Index
Yıl2021
Atıf11OpenAlex
Atıf12Semantic Scholar · 3 etkili
Yüzdelik%75,9
FWCI1,091,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q3

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıTURKISH JOURNAL OF MEDICAL SCIENCES
  • Katalog eşleşmesi (ISSN)Turkish Journal of Medical Sciences
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Background/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis and endothelial dysfunction in patients with AS. Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods. Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with BASDAI (p < 0.001), and BASFI (p < 0.001). Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin levels may be associated with subclinical atherosclerosis in AS.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

11atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 12 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2023 Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitisAtıf 8 · OpenAlex
  2. 2023 Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitisAtıf 8 · OpenAlex
  3. 2022 Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitisAtıf 8 · OpenAlex
  4. 2026 Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndromeAtıf 6 · OpenAlex
  5. 2024 Cardiovascular Risk in Patients with Ankylosing SpondylitisAtıf 4 · OpenAlex
  6. 2024 Cardiovascular Risk in Patients with Ankylosing SpondylitisAtıf 4 · OpenAlex
  7. 2024 Cardiovascular Risk in Patients with Ankylosing SpondylitisAtıf 3 · OpenAlex
  8. 2022 Validation and cross-cultural adaptation of the Turkish version of the revised Leeds Disability Questionnaire in patients with ankylosing spondylitisAtıf 3 · OpenAlex
  9. 2022 Validation and cross-cultural adaptation of the Turkish version of the revised Leeds Disability Questionnaire in patients with ankylosing spondylitisAtıf 3 · OpenAlex
  10. 2022 Validation and cross-cultural adaptation of the Turkish version of the revised Leeds Disability Questionnaire in patients with ankylosing spondylitisAtıf 2 · OpenAlex

Yazarlar

7
  1. RABİA AYDOĞAN BAYKARA 1
  2. ADEM KÜÇÜK NECMETTİN ERBAKAN ÜNİVERSİTESİ 2
  3. AYÇA TUZCU 3
  4. GÖKSEL TUZCU AYDIN ADNAN MENDERES ÜNİVERSİTESİ 4
  5. ERKAN CÜRE 5
  6. ALİ UĞUR USLU 6
  7. AHMET OMMA 7